127943-83-3Relevant articles and documents
STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES
-
Paragraph 00816, (2017/01/09)
The application relates to compounds of Formula (I'): which modulate the activity of a kinase (e.g., STK4), a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease or disorder associated with the modulation of a kinase, such as STK4.
Synthesis of N-(phenylsulfonyl)-CI, N-((tert-butyloxy)carbonyl)-CI, CI-CDPI 1, and CI-CDPI 2: CC-1065 functional analogues incorporating the parent 1,2,7,7a-tetrahydrocycloprop[1,2-c]indol-4-one (CI) left-hand subunit
Boger, Dale L.,Wysocki Jr., Ronald J.,Ishizaki, Takayoshi
, p. 5230 - 5240 (2007/10/02)
Full details of the synthesis of N-(phenylsulfonyl)- and N-((tert-butyloxy)carbonyl)-1,2,7,7a-tetrahydrocycloprop[1,2-c]indol-4-one [N-(phenylsulfonyl)-CI (9) and N-BOC-CI (10)] constituting stable derivatives of the parent cyclopropylcyclohexadienone rin